Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hasford, J
Right arrow Articles by Thaler, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hasford, J
Right arrow Articles by Thaler, J
Haematologica, Vol 90, Issue 3, 335-340
Copyright © 2005 by Ferrata Storti Foundation

Journal Article

The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha

J Hasford, M Pfirrmann, P Shepherd, J Guilhot, R Hehlmann, FX Mahon, HC Kluin-Nelemans, K Ohnishi, JL Steegmann, and J Thaler

Universite Victor Segalen, Bordeaux, France; University Hospital Groningen, Groningen, The Netherlands. has@ibe.med.uni-muenchen.de

BACKGROUND AND OBJECTIVES: This study was aimed at examining major cytogenetic response (MCR) as a valid predictor of the course of chronic myeloid leukemia (CML) and at assessing the survival of CML patients treated with interferon alpha (IFN) in dependence on the combination of MCR (yes or no) with the baseline risk group of the New CML score. MCR was defined as a reduction of Philadelphia chromosome-positive bone marrow cells to


This article has been cited by other articles:


Home page
 BloodHome page
C. S. Tam, H. Kantarjian, G. Garcia-Manero, G. Borthakur, S. O'Brien, F. Ravandi, J. Shan, and J. Cortes
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
Blood, August 1, 2008; 112(3): 516 - 518.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Roy, J. Guilhot, T. Krahnke, A. Guerci-Bresler, B. J. Druker, R. A. Larson, S. O'Brien, C. So, G. Massimini, and F. Guilhot
Survival advantage from imatinib compared with the combination interferon-{alpha} plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials
Blood, September 1, 2006; 108(5): 1478 - 1484.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.